Literature DB >> 22015789

[Prerequisites for electronic systems evaluating safe and effective drug therapy. A contribution to the Action Plan of the Federal Health Ministry].

A-F Aly1, K Menges, C H Haas, L Zimmermann, J Kaltschmidt, M Criegee-Rieck.   

Abstract

Evaluation of effective and safe drug therapy assisted by electronic systems is based on certain prerequisites, including structured data of drugs and from patients. These prerequisites were identified in a workshop within the scope of the National Action Plan and have been reported in a 7+1-point plan: medicinal product data must be correct and up-to-date based on the summary of product characteristics approved by the responsible authorities. Product data must be available in an agreed textual structure and must use defined semantic elements within this structure. Identifiers must be allocated to all drugs and substances in order to enable unique identification and exchange across systems. Semantic structures of the product data, on the one hand, and of patient data, on the other, must be defined across system boundaries and for the whole German national health care system, and be available to every stakeholder, up-to-date, and preferably freely accessible. This consensus regarding content and structural conventions is a prerequisite for other scenarios in the health care system, such as transmitting individual case safety reports without system and media discontinuity, and is currently of great importance with respect to the European legislation on pharmacovigilance, which will be implemented nationally.

Entities:  

Mesh:

Year:  2011        PMID: 22015789     DOI: 10.1007/s00103-011-1337-7

Source DB:  PubMed          Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz        ISSN: 1436-9990            Impact factor:   1.513


  1 in total

1.  Effects of Shared Electronic Health Record Systems on Drug-Drug Interaction and Duplication Warning Detection.

Authors:  Christoph Rinner; Wilfried Grossmann; Simone Katja Sauter; Michael Wolzt; Walter Gall
Journal:  Biomed Res Int       Date:  2015-11-22       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.